News | January 22, 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
The drug is priced at Rs 2000 for a course of 40 tablets
The brand is now available pan-India through their distribution partner
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
DCGI approved the drug based on the review of clinical data
The drug will be marketed under the brand name Molnaflu
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
